Home
Search
Search Results
Previously Searched
3113 results found
Expand All
Apply All
3113 results found

BIO Statement on Vaccines and Autism
Letters, Testimony & Comments  •  September 23, 2025
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating infectious diseases like smallpox, polio, and measles. Today’s pediatric vaccination schedule is specifically designed to protect American children during their period of greatest risk to infectious diseases.  “Additionally, extensive scientific research with hundreds of peer-reviewed studies and continuous safety monitoring over decades have consistently shown that vaccines and their ingredients do not cause autism. To continue suggesting there is a link without evidence is a disservice to finding causes and interventions that could help those living with autism and the families who support them. These suggestions will also cause confusion and erode confidence in vaccines with American families, exposing millions of people, particularly children, to the risk of being unprotected to serious infectious disease.”
Read More

House passes SBIR/STTR reauthorization
Good Day BIO Newsletter  •  September 22, 2025
The House passed a one-year reauthorization of the SBIR/STTR programs that BIO supports. Also, BIO hits the road in Texas. (730 words, 3 minutes, 39 seconds)
Read More

Become a BIO Member

Online Membership Application
BIO membership is available only to bona fide organizations that promote biotechnology research and support the growth and development of the biotechnology industry; and to organizations with public policy positions and business practices that are generally consistent with BIO’s reputation and its policies and principles in support of innovation, including intellectual property, as determined by the Board Standing Committee on Membership & International Convention. BIO reserves the right to review applications for membership to confirm that the applicant meets these criteria for membership, and for the specified categories of membership as per BIO’s bylaws. BIO may, in its sole discretion, reject an application for membership or elect not to renew a membership.Membership Application Form to Fill & Email (168 KB PDF | Get Acrobat Reader)Please note: Membership applications are manually processed and it may take between 2-3 business days. Our team will follow up with an invoice and additional information if approved. html legend { display: block; font-size: 15px; font-family: "Poppins",sans-serif; } (function() { var didInit = false; function initMunchkin() { if(didInit === false) { didInit = true; Munchkin.init('490-EHZ-999'); } } var s = document.createElement('script'); s.type = 'text/javascript'; s.async = true; s.src = '//munchkin.marketo.net/munchkin.js'; s.onreadystatechange = function() { if (this.readyState == 'complete' || this.readyState == 'loaded') { initMunchkin(); } }; s.onload = initMunchkin; document.getElementsByTagName('head')[0].appendChild(s); })();
Read More

Patients Pay. Middlemen Take. Innovation Loses.
Human Health, Government Price Setting  •  Toolkit  •  September 19, 2025
America leads the world in biotechnology innovation. Yet the U.S. remains the only country where half of every dollar spent on medicine goes to middlemen and supply chain markups - rather than to patients or innovation.
Read More

PBM Reform: What it Means for Access to Biotech Innovation & Patients

BIO Business Solutions - BIO's Cost-Savings Program
BIO Business Solutions

BIO Extends Agreement with Avantor for Five Additional Years.
Press Release  •  September 17, 2025
Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The Biotechnology Innovation Organization (BIO) today announced it has extended its agreement with Avantor, a leading life sciences tools company and global provider of mission-critical products and services to the life sciences and technology industries, for an additional five years. The extension builds on more than two decades of collaboration, delivering exceptional value to members of BIO and state and regional biotechnology associations through exclusive cost-saving programs and enhanced access to innovative solutions.Through this agreement, BIO members gain access to contracted pricing and discounts on millions of products from Avantor’s robust supplier network, as well as preferred shipping terms, special service savings, dedicated customer service support, and growth and eCommerce rebates. The agreement is part of BIO’s ongoing commitment to helping its members advance science and enact meaningful change.  “BIO is committed to advancing cures, treatments, and innovations, and a critical way we do that is by removing operational hurdles for our members,” said John F. Crowley, President and CEO of BIO. “Extending our agreement with Avantor ensures that our member companies, regardless of size, can access the tools, supplies, and support they need to make scientific breakthroughs and improve the lives of people and patients around the world.”Avantor’s offerings include a comprehensive portfolio of laboratory consumables, equipment and instruments, productivity-enhancing technology and global manufacturing and distribution capabilities that support every step of the scientific journey. The collaboration with BIO allows both emerging and established biotech organizations to access Avantor’s full portfolio of offerings at competitive rates.“We are honored to…
Read More

BIO's Comments to CDC’s Advisory Committee on Immunization Practices (ACIP)
Letters, Testimony & Comments  •  September 17, 2025
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in advance of the September 18-19th, 2025 meeting. BIO submits this comment to reaffirm the importance of ACIP’s established evidence-based processes and their critical role in safeguarding American health and vaccine access. In short, BIO encourages continued excellence in the work done by ACIP by adhering to the established steps that lend weight and legitimacy to ACIP’s recommendations. These steps are part of a system that has contributed to decades of progress in protecting Americans against deadly infectious diseases.
Read More

BIO frequently provides webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services. Recordings of prior BIO
BIO frequently provides webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services. Recordings of prior BIO webinars are searchable below.
Read More